miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 14, Issue 2, Pages 89
Publisher
MDPI AG
Online
2021-01-26
DOI
10.3390/ph14020089
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
- (2020) Xiao-Xiao Peng et al. Journal for ImmunoTherapy of Cancer
- Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
- (2020) Florian Huemer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
- (2020) Gabriel Rinnerthaler et al. Journal of Clinical Medicine
- Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC
- (2020) Takehito Shukuya et al. Journal of Thoracic Oncology
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia
- (2020) Franz J. Gassner et al. LEUKEMIA
- LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
- (2020) K. Kato et al. ANNALS OF ONCOLOGY
- 1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer
- (2020) C. Genova et al. ANNALS OF ONCOLOGY
- LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study
- (2020) R.J. Kelly et al. ANNALS OF ONCOLOGY
- LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
- (2020) M. Moehler et al. ANNALS OF ONCOLOGY
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
- (2020) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- (2020) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo
- (2020) Eleni Anastasiadou et al. CLINICAL CANCER RESEARCH
- Circulating microRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective study
- (2019) Mattia Boeri et al. CLINICAL CANCER RESEARCH
- MicroRNA replacement therapy in cancer
- (2019) Homa Mollaei et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer
- (2019) Ivy X. Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
- (2019) Yongwoo David Seo et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells
- (2019) Zhong Zheng et al. Molecular Cancer
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- miR-149-3p reverses CD8 + T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells
- (2019) Meng Zhang et al. Open Biology
- The Non-Canonical Aspects of MicroRNAs: Many Roads to Gene Regulation
- (2019) Christiaan J. Stavast et al. Cells
- The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation
- (2019) Dan Yu et al. Cell Communication and Signaling
- Deciphering miRNAs’ Action through miRNA Editing
- (2019) Marta Correia de Sousa et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells
- (2019) Peng-Fei Zhang et al. Molecular Cancer
- Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
- (2018) Ann Rita Halvorsen et al. ACTA ONCOLOGICA
- Development and validation of a plasma-based melanoma biomarker suitable for clinical use
- (2018) Ryan Van Laar et al. BRITISH JOURNAL OF CANCER
- miR-125b-5p and miR-99a-5p downregulate human γδ T-cell activation and cytotoxicity
- (2018) Yuli Zhu et al. Cellular & Molecular Immunology
- Serum exosomal microRNAs as potent circulating biomarkers for melanoma
- (2018) Li Tengda et al. MELANOMA RESEARCH
- A-to-I RNA editing — immune protector and transcriptome diversifier
- (2018) Eli Eisenberg et al. NATURE REVIEWS GENETICS
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy
- (2018) Jiajia Xi et al. ONCOGENE
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma
- (2018) Anita G. Seto et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- 9PIdentification of serum microRNAs predicting the response to nivolumab in patients with advanced gastric cancer
- (2018) T Miyamoto et al. ANNALS OF ONCOLOGY
- miR-146a Controls Immune Response in the Melanoma Microenvironment
- (2018) Justin Mastroianni et al. CANCER RESEARCH
- Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk
- (2018) Orazio Fortunato et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma
- (2018) Veronica Huber et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- miRBase: from microRNA sequences to function
- (2018) Ana Kozomara et al. NUCLEIC ACIDS RESEARCH
- Antitumor immunity is defective in T cell–specific microRNA-155–deficient mice and is rescued by immune checkpoint blockade
- (2017) Thomas B. Huffaker et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
- (2017) Steven C. Kao et al. Journal of Thoracic Oncology
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
- (2017) Toshihiro Kudo et al. LANCET ONCOLOGY
- Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
- (2017) Nico van Zandwijk et al. LANCET ONCOLOGY
- Dynamic landscape and regulation of RNA editing in mammals
- (2017) Meng How Tan et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection
- (2016) Zhen Huang et al. BIOMATERIALS
- Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
- (2016) Muhammad S. Beg et al. INVESTIGATIONAL NEW DRUGS
- MiR-16 regulates mouse peritoneal macrophage polarization and affects T-cell activation
- (2016) Xiaoqin Jia et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- MicroRNA-320 was downregulated in non-small cell lung cancer and inhibited cell proliferation, migration and invasion by targeting fatty acid synthase
- (2016) Ting Lei et al. Molecular Medicine Reports
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
- (2016) Lian Zhao et al. Oncotarget
- miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion
- (2016) Qing Li et al. Oncotarget
- Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer
- (2015) T F Hansen et al. BRITISH JOURNAL OF CANCER
- The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers
- (2015) Leng Han et al. CANCER CELL
- Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis
- (2015) Einav Shoshan et al. NATURE CELL BIOLOGY
- MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints
- (2015) Jun Wei et al. NEURO-ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- miR-15b/16-2 deletion promotes B-cell malignancies
- (2015) Francesca Lovat et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening
- (2015) Stefano Sestini et al. Oncotarget
- A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
- (2015) Gilli Galore-Haskel et al. Oncotarget
- Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors
- (2015) Nurit Paz-Yaacov et al. Cell Reports
- Role of miR-15/16 in CLL
- (2014) Y Pekarsky et al. CELL DEATH AND DIFFERENTIATION
- Clinical Utility of a Plasma-Based miRNA Signature Classifier Within Computed Tomography Lung Cancer Screening: A Correlative MILD Trial Study
- (2014) Gabriella Sozzi et al. JOURNAL OF CLINICAL ONCOLOGY
- miR-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma
- (2013) Jun Wei et al. CANCER RESEARCH
- Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
- (2013) J.B. Kjersem et al. Molecular Oncology
- MicroRNAs
- (2013) M. Bhaskaran et al. VETERINARY PATHOLOGY
- Effects of ADARs on small RNA processing pathways in C. elegans
- (2012) M. B. Warf et al. GENOME RESEARCH
- MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1
- (2012) Yongkui Li et al. Protein & Cell
- MicroRNA 92a-2*: A Biomarker Predictive for Chemoresistance and Prognostic for Survival in Patients with Small Cell Lung Cancer
- (2010) Aarati R. Ranade et al. Journal of Thoracic Oncology
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215
- (2008) S. A. Georges et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now